TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Telomir Pharmaceuticals, Inc. ( (TELO) ).
On October 22, 2025, Telomir Pharmaceuticals announced preclinical data indicating that its compound Telomir-1 outperformed Rapamycin and chemotherapy in an aggressive prostate cancer model by modulating DNA methylation of key genes CASP8 and GSTP1. The study suggests that Telomir-1 may enhance apoptosis and detoxification pathways, potentially improving chemotherapy outcomes and offering new insights into cancer treatment strategies.
The most recent analyst rating on (TELO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.
More about Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on oncology research. The company develops investigational compounds like Telomir-1, which targets cancer defense systems through DNA methylation modulation.
Average Trading Volume: 2,949,884
Technical Sentiment Signal: Sell
Current Market Cap: $53.59M
See more data about TELO stock on TipRanks’ Stock Analysis page.